Second Sight Medical (EYES) Announces Two-Year Results of its Orion Study
- Wall Street dips after S&P 500 hits record high; Fed meeting in focus
- DraftKings (DKNG) Plunges as Hindenburg's Report Indicates Betting Company's Links to Black Market Operations
- U.S. retail sales fall as spending shifts back to services; producer prices rise
- ZoomInfo (ZI) Gains After Setting $2 Billion 2025 Sales Target, Analysts Positive
- Oil trades at multi-year highs on demand expectations
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced two-year results of its Early Feasibility Study (Study) of the Orion Visual Cortical Prosthesis (Orion). The Study is a single arm six subject study at UCLA and Baylor College of Medicine. The Study was paused due to the COVID-19 pandemic, but is now resumed at both centers. All subjects are still enrolled in the Study and recent visual function and functional vision results continue to demonstrate that a majority of participants benefit from Orion. Five out of five of those tested at the two-year mark are able to locate a white square on a dark computer screen significantly better with the Orion System on than with it off. Four out of five of those tested at the two-year mark are able to better identify the direction of motion of a bar moving across a computer screen with the Orion System on. The Functional Low-Vision Observer Rated Assessment (FLORA) has only been performed with two subjects due to COVID-19 travel restrictions, but both were rated as receiving mild positive or positive benefit from the Orion in real-world settings. The remaining 24-month visits are currently being scheduled. There has been only one serious adverse event early in the Study. The event was completely resolved without hospitalization.
“We are excited to resume the study and see such promising results, especially after all visits were paused for several months due to COVID-19,” said Jessy Dorn, Vice President of Clinical and Scientific Research at Second Sight.
Nader Pouratian, a principal investigator on the Orion clinical trial and Professor and Chair of Neurological Surgery at UT Southwestern Medical Center, added, “We have learned about the therapeutic potential of Orion from the results of this early feasibility study and feel they support progress toward a larger study.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ocugen (OCGN) Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN
- NRx Pharmaceuticals (NRXP) Announces Positive Data Results from ZYESAMI Expanded Access Protocol
- INVO Bioscience (INVO) Appoints Andrea Goren as Chief Financial Officer
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!